| Daniel L Dettman, | |
|
Unit 33100 Box Landstuhl, Apo, AE 09180-3100 | |
| (406) 600-5463 | |
| Not Available |
| Full Name | Daniel L Dettman |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | Unit 33100 Box Landstuhl, Apo, Armed Forces Europe |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538778832 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| 225100000X | Physical Therapist | 046683-01 (New York) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Daniel L Dettman, Unit 33100 Box Landstuhl, Apo, AE 09180-3100 Ph: () - | Daniel L Dettman, Unit 33100 Box Landstuhl, Apo, AE 09180-3100 Ph: (406) 600-5463 |
News Archive
Childhood bullying can lead to long term health consequences, including general and mental health issues, behavioral problems, eating disorders, smoking, alcohol use, and homelessness, a study by the Crime Victims' Institute at Sam Houston State University found.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today an exclusive partnership agreement with Therabel Group for the European commercialization rights of Loramyc® and Setofilm® including France and the associated French commercial structure to a newly established entity, Therabel Hôpital Pharma.
Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.
Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.
› Verified 3 days ago
Joseph Frjelich, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Hq Meddac Bavaria, Unit 28037 Bldg 700, Apo, AE 09112 Phone: 314-590-2368 | |
Emily Ward, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Usahc Vicenza, Apo, AE 09630 Phone: 339-619-7896 | |
Jenna Marie Boyd, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Unit 3215, Apo, AE 09094 Phone: 314-479-2609 | |
Dr. Ashlyn Owens Hull, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: U.s. Army Health Clinic Hohenfels Unit 28216 Hohenfels,, Apo, AE 09173 Phone: 314-590-3300 | |
Maria Lebron, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc 94, Apo, AE 09824 Phone: 011-903-163223380 | |
Dr. Nicoleta Grigoras, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Unit 33100, Apo, AE 09180 Phone: 314-590-8298 | |
Susan Kay Oppliger, PHYSICAL THERAPIST Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Landstuhl Regional Medical Center, Attn:mceul-dccs (credentials), Apo, AE 09180 Phone: 011-496-78366710 |